The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting ca...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Chen, Xi, Xu, Zhijie, Zeng, Shuangshuang, Wang, Xiang, Liu, Wanli, Qian, Long, Wei, Jie, Yang, Xue, Shen, Qiuying, Gong, Zhicheng, Yan, Yuanliang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2019
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6733886/
https://ncbi.nlm.nih.gov/pubmed/31552177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00852
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia